References
- Chen Y, Estrov Z, Pierce S, et al. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor. Leuk Lymphoma 2015;56:1012–1019.
- Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114: 937–951.
- Klimek VM. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 2013;20:1374143.
- Massberg S, von Andrian UH. Novel trafficking routes for hematopoietic stem and progenitor cells. Ann NY Acad Sci 2009;1176:87–93.
- Mukherjee S, Reddy CA, Ciezki JP, et al. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation. J Natl Cancer Inst 2014;106:djt462.
- Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352:930–942.
- Nardi V, Winkfield KM, Ok CY, et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012;30:2340–2347.
- Iwanaga M, Hsu WL, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011;29:428–434.